




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/72, 38/29, 47/12</b>		A1	(11) International Publication Number: <b>WO 96/19206</b>
			(43) International Publication Date: 27 June 1996 (27.06.96)
(21) International Application Number: <b>PCT/SE95/01475</b>			(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).
(22) International Filing Date: 8 December 1995 (08.12.95)			
(30) Priority Data: 9404449-2 22 December 1994 (22.12.94) SE 9502576-3 12 July 1995 (12.07.95) SE			
(71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).			Published With international search report.
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BÄCKSTRÖM, Kjell [SE/SE]; Notariegränden 4, S-226 47 Lund (SE). WALLMARK, Björn [SE/SE]; Råda Portar 97, S-435 00 Mölnlycke (SE).			
(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).			

(54) Title: THERAPEUTIC PREPARATION FOR INHALATION CONTAINING PARATHYROID HORMONE, PTH



## (57) Abstract

The present invention relates to compositions and methods for pulmonary administration of full-length parathyroid hormone to mammalian hosts for the treatment of osteoporosis. Thus there is provided a therapeutic preparation comprising a human full-length parathyroid hormone, or homologues thereof, in the form of a dry powder suitable for inhalation in which at least 50 % of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates of such particles.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

**Therapeutic preparation for inhalation containing  
parathyroid hormone, PTH.**

**TECHNICAL FIELD**

5      The present invention relates to compositions and methods for pulmonary administration of parathyroid hormone (parathormone, PTH) to mammalian hosts for the treatment of osteoporosis.

**10     BACKGROUND ART**

Human parathyroid hormone is an 84 amino acid protein (SEQ ID NO: 1) involved in calcium and phosphorus homeostasis and control of bone growth and density. Human PTH may be obtained through peptide synthesis or from genetically engineered yeast, bacterial or mammalian cell hosts. Human PTH is also commercially available from Bachem Inc., Bubendorf, Switzerland. Production of recombinant human parathyroid hormone is disclosed in EP-B-0383751.

20     In mammals, the balance between bone formation, associated with the activity of osteoblasts, on one hand, and bone loss, associated with the activity of osteoclasts, on the other hand, is disturbed in several bone affecting diseases, such as osteoporosis. Parathyroid hormone has been shown to have a potential therapeutic role in osteoporosis. The anabolic actions of parathyroid hormone on bone are reviewed in Dempster et al. 25 (1993) Endocrine Reviews, vol. 14, 690-709.

30     The N-terminal fragment of human PTH (PTH 1-34) was shown to have an anabolic effect on trabecular bone in involutional osteoporosis by Reeve et al. (1980) British Medical Journal, vol. 280, 1340-1344. However, the administration of a wild-type protein is to be preferred when possible,

-2-

since this will ensure that all biological effects of the natural protein are exerted by the administered compound.

5 Polypeptide drugs such as PTH cannot be orally administered in effective doses, since they are rapidly degraded by enzymes in the gastrointestinal tract, and by the low pH in the stomach, before they can reach the bloodstream. Administration of PTH has generally been accomplished subcutaneously by injection. However, injection on a daily basis is 10 inconvenient for the patient. Because of these disadvantages, there is a need for PTH in a form which is administrable other than by injection.

15 Pulmonary delivery of parathyroid hormone and N-terminal fragments thereof to rats is disclosed in WO 94/07514. When the N-terminal fragment consisting of amino acids 1-34 (PTH34) was administered to rats intratracheally (IT), the serum profile exhibited a peak after 15 minutes with activity diminishing rapidly thereafter. In contrast, the serum profile after IT administration of full-length PTH (PTH84) exhibited a plateau which did not diminish significantly during the 90 minutes of the 20 experiment. Since it is known that PTH is most effectively delivered to a patient in pulsatile fashion, i.e. serum concentrations should rise rapidly after administration and fall rapidly after a peak has been reached, it is concluded in the document WO 94/07514 that N-terminal fragments of PTH is preferred over the full-length protein for pulmonary delivery.

25

#### SUMMARY OF THE INVENTIVE CONCEPT

According to the present invention it has been shown that a pulsative plasma profile is obtained when full-length PTH as a dry powder aerosol 30 is inhaled via an endotracheal tube by dogs. It has thus surprisingly been shown that pulmonary administration of full-length PTH, contrary to the conclusions expressed in the published patent application WO 94/07514,

—3—

will be effective for stimulating bone formation and for the treatment of osteoporosis.

5      BRIEF DESCRIPTION OF THE DRAWING

Fig.1

Plasma concentration in dogs after inhalation of PTH 1-34 and PTH 1-84, respectively. (—■—) PTH 1-84 (inhaled dose 14 µg/kg); (..▲..) PTH 1-34 (inhaled dose 4.0 µg/kg).

DISCLOSURE OF THE INVENTION

15     In a first aspect of the invention there is provided a therapeutic material, which preferably is a therapeutic preparation, comprising a parathyroid hormone having substantially the biological activities of full-length parathyroid hormone. The said therapeutic material is in the form of a dry powder suitable for inhalation in which at least 50% of the total mass of

20     the active compound PTH consists of (a) primary particles having a diameter of less than about 10 microns, for example between 0.01 and 10 microns, and preferably between 1 and 6 microns, or (b) agglomerates of said particles.

25     The therapeutic preparation of the present invention may contain only the said active compound PTH, or it may contain other substances, such as a pharmaceutically acceptable carrier. This carrier may largely consist of particles having a diameter of less than about 10 microns, so that at least 50% of the resultant powder as a whole consists of optionally

30     agglomerated primary particles having a diameter of less than about 10 microns, for example between 0.01 and 10 microns, and preferably between 1 and 6 microns, or (b) agglomerates of said particles.

—4—

Alternatively, the carrier may largely consist of much bigger particles ("coarse particles"), so that an "ordered mixture" may be formed between the active compounds and the said carrier. In an ordered mixture, alternatively known as an interactive or adhesive mixture, fine drug 5 particles (in this invention, the active compounds) are fairly evenly distributed over the surface of coarse excipient particles (in this invention, the pharmaceutically acceptable carrier). Preferably in such case the active compounds are not in the form of agglomerates prior to formation of the ordered mixture. The coarse particles may have a diameter of over 20 10 microns, such as over 60 microns. Above these lower limits, the diameter of the coarse particles is not of critical importance so various coarse particle sizes may be used, if desired according to the practical requirements of the particular formulation. There is no requirement for the coarse particles in the ordered mixture to be of the same size, but the 15 coarse particles may advantageously be of similar size within the ordered mixture. Preferably, the coarse particles have a diameter of 60 - 800 microns.

Preferably at least 60%, such as at least 70% or at least 80%, and more 20 preferably at least 90% of the total mass of the active compound PTH consists of particles having a diameter of less than about 10 microns, or of agglomerates of such particles. When the dry powder preparation comprises carrier, other than when an ordered mixture is desired, preferably at least 60%, such as at least 70% or at least 80%, and more 25 preferably at least 90% by mass of the total dry powder consists of particles having a diameter of less than about 10 microns, or of agglomerates of such particles.

While the dry powder for inhalation, whether with or without 30 pharmaceutically acceptable carrier, may contain agglomerates of particles as indicated above, at the time of inhalation any agglomerates should be substantially deagglomerated yielding a powder of which at least 50%

—5—

consists of particles having a diameter of up to 10 microns. The agglomerates can be the result of a controlled agglomeration process or they may simply be the result of the intimate contact of the powder particles. In either case it is essential that the agglomerates are capable of 5 being de-agglomerated e.g. by mechanical means in the inhaler or otherwise, into the aforesaid particles. Agglomerates are in general preferably not formed in the ordered mixture. In the case of an ordered mixture, the active compounds should be released from the large particles preferably upon inhalation, either by mechanical means in the inhaler or 10 simply by the action of inhalation, or by other means, the active compounds then being deposited in the lower respiratory tract and the carrier particles in the mouth.

When desirable, it will be possible to include in the preparation a 15 substance which enhances the absorption of PTH in the lower respiratory tract. Such a substance can be any of a number of compounds which act to enhance absorption through the layer of epithelial cells lining the alveoli of the lungs and into the adjacent pulmonary vasculature. Examples of enhancers are salts of fatty acids, e.g. sodium caprate, bile salts and 20 derivatives thereof; phospholipids; chelators; and cyclodextrins and derivatives thereof. Additional examples of suitable enhancers can be found in the International Patent Applications WO 95/00127 and WO 95/00128.

25 The parathyroid hormone to be used according to the invention is preferably a human parathyroid hormone, although any biologically active form or derivative of PTH, having substantially the biological activities of full-length parathyroid hormone, may be used.

30 Preferably, the PTH to be used according to the invention is a parathyroid hormone which comprises at least amino acids 1 to 34, more preferably amino acids 1 to 84, of the sequence shown as SEQ ID NO: 1 in the

Sequence Listing. However, the PTH to be used according to the invention is not to be limited strictly to PTH having the sequence shown in the Sequence Listing. Rather the invention encompasses use of PTH polypeptides carrying modifications like substitutions, small deletions, 5 insertions or inversions, which polypeptides nevertheless have substantially the biological activities of the full-length PTH which amino acid sequence is disclosed in the Sequence Listing. Included in the invention are consequently also the use of polypeptides, the amino acid sequence of which is at least 90% homologous, preferably at least 95% 10 homologous, with the amino acid sequence shown in the Sequence Listing. Modifications of full-length PTH can be developed in order to improve various properties, for example to improve stability or give an improved pharmacokinetic profile (i.e. improved profile of absorption through the epithelial membranes).

15 As stated above, additive substances commonly included in therapeutic preparations, such as pharmaceutically acceptable carriers, may be included in the therapeutic preparation of the present invention. Additive substances may be included for example in order to dilute the powder to an amount which is suitable for delivery from the particular intended 20 powder inhaler; to facilitate the processing of the preparation; to improve the powder properties of the preparation; to improve the stability of the preparation, e.g. by means of antioxidantia or pH-adjusting compounds; or to add a taste to the preparation. Any additive should not adversely affect 25 the stability of PTH, or disadvantageously interfere with absorption of PTH. It should also be stable, not hygroscopic, have good powder properties and have no adverse effects in the airways.

30 As examples of potential additives may be mentioned mono-, di-, and polysaccharides, sugar alcohols and other polyols, such as for example lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose,

-7-

mannitol and starch. Depending upon the inhaler to be used, the total amount of such additives may vary over a very wide range.

5 In some circumstances little or no additive would be required, whereas for example in the case of an inhaler requiring large powder volumes for operation, a very high percentage of the therapeutic preparation could consist of additive. The amount of additive desirable would be easily determined by a person skilled in the art according to particular circumstances.

10

A useful mechanism for delivery of the powder according to the invention into the lungs of a patient is through a portable inhaler device suitable for dry powder inhalation. Many such devices, typically designed to deliver antiasthmatic or antiinflammatory agents into the respiratory system, are 15 on the market. Preferably the device is a dry powder inhaler of a design which provides protection of the powder from moisture and has no risk for overdosing, i.e. for occasional large doses. In addition as many as possible of the following characteristics are desired: protection of the powder from light; high respirable fraction and high lung deposition in a 20 broad flow rate interval; low deviation of dose and respirable fraction; low retention of powder in the mouthpiece; low adsorption to the inhaler surfaces; flexibility in dose size; and low inhalation resistance.

25

The inhaler is preferably a single dose inhaler although a multi dose inhaler, preferably such as a multi dose, breath actuated, dry powder inhaler for multiple use, may also be employed. A suitable multi dose inhaler is described in EP-B-0069715 and in EP-B-0237507. Preferably the inhaler used is a unit dose, breath actuated, dry powder inhaler for single use. A preferable unit dose inhaler is described in EP-A-0548166 and in EP-30 A-0558879.

-8-

Consequently, a further aspect of the invention is the use of a therapeutic preparation according to the invention in an inhalation device. Preferably, the said inhalation device provides protection of the powder for inhalation from moisture, and has minimal risk of overdosing. The said inhalation 5 device can be e.g. a unit dose, breath actuated, dry powder inhaler for single usage, or a multi dose, breath actuated, dry powder inhaler for multiple use.

10 Yet a further aspect of the invention is a dry powder inhalation device containing the therapeutic preparation as defined above.

A further important aspect of the invention is a process for the manufacture of a therapeutic preparation as defined above. The described powder preparation can be manufactured in several ways, using 15 conventional techniques. It may be necessary to micronise the active compounds and if appropriate (i.e where an ordered mixture is not intended) any carrier in a suitable mill, for example in a jet mill at some point in the process, in order to produce primary particles in a size range appropriate for maximal deposition in the lower respiratory tract (i.e., under 10  $\mu\text{m}$ ). For example, one can dry mix PTH and carrier, where 20 appropriate, and then micronise the substances together; alternatively, the substances can be micronised separately, and then mixed. Where the compounds to be mixed have different physical properties such as hardness and brittleness, resistance to micronisation varies and they may 25 require different pressures to be broken down to suitable particle sizes. When micronised together, therefore, the obtained particle size of one of the components may be unsatisfactory. In such case it would be advantageous to micronise the different components separately and then mix them.

30

It is also possible first to dissolve the active component including, where an ordered mixture is not intended, any carrier in a suitable solvent, e.g.

water, to obtain mixing on the molecular level. This procedure also makes it possible to adjust the pH-value to a desired level. The pharmaceutically accepted limits of pH 3.0 to 8.5 for inhalation products must be taken into account, since products with a pH outside these limits may induce

5 irritation and constriction of the airways. To obtain a powder, the solvent must be removed by a process which retains the biological activity of PTH. Suitable drying methods include vacuum concentration, open drying, spray drying, freeze drying and use of supercritical fluids. Temperatures over 40°C for more than a few minutes should generally be avoided, as some

10 degradation of the PTH may occur. Following the drying step, the solid material can, if necessary, be ground to obtain a coarse powder, then, if necessary, micronised.

If desired, the micronised powder can be processed to improve the flow

15 properties, e.g., by dry granulation to form spherical agglomerates with superior handling characteristics, before it is incorporated into the intended inhaler device. In such a case, the device would be configured to ensure that the agglomerates are substantially deagglomerated prior to exiting the device, so that the particles entering the respiratory tract of the patient are

20 largely within the desired size range.

Where an ordered mixture is desired, the active compound may be processed, for example by micronisation, in order to obtain, if desired, particles within a particular size range. The carrier may also be processed,

25 for example to obtain a desired size and desirable surface properties, such as a particular surface to weight ratio, or a certain ruggedness, and to ensure optimal adhesion forces in the ordered mixture. Such physical requirements of an ordered mixture are well known, as are the various means of obtaining an ordered mixture which fulfils the said requirements,

30 and may be determined easily by the skilled person according to the particular circumstances.

—10—

Yet a further aspect of the invention is a method for the treatment of osteoporosis comprising administering, to a patient in need thereof, an effective amount of a therapeutic preparation as defined above. Suitable doses can be in the range of 1 to 100 µg full-length PTH / kg, e.g. around 5 30 µg/kg.

The invention will now be described by way of Examples, which are intended to illustrate but not limit the scope of the invention.

10

## EXAMPLES

### EXAMPLE 1

15 1.1. *Therapeutic preparation of PTH 1-84 for inhalation*

An aqueous solution with the following composition is made:

Human PTH 1-84	41 mg
Citric acid, monohydrate	57 mg
20 Sodium citrate	113 mg
Lactose	3888 mg
Water	approx. 53 ml

25 The pH is adjusted to 5.0. The solution is concentrated by evaporation, at a temperature of 37°C, over a period of about one day. The obtained solid cake is crushed and sieved through a 0.5 mm sieve, and the resultant powder micronised through a jet mill to particles of about 2 microns in diameter.

-11-

**1.2. Therapeutic preparation of PTH 1-34 for inhalation**

An aqueous solution with the following composition is made:

	Human PTH 1-34	11.2 mg
5	Citric acid, monohydrate	66 mg
	Sodium citrate	131 mg
	Lactose	4589 mg
	Water	approx. 52 ml

10 The solution is further treated as described in Example 1.1. above.

**1.3. Therapeutic PTH preparation including an enhancer**

An aqueous solution with the following composition is made:

15	Human PTH 1-84	50 mg
	Citric acid, monohydrate	69 mg
	Sodium citrate	138 mg
	Sodium taurocholate	17 mg
	Lactose	4726 mg
20	Water	approx. 60 ml

The pH is adjusted to 5.0. The solution is concentrated by evaporation, at a temperature of 37°C, over a period of about one day. The obtained solid cake is crushed and sieved through a 0.5 mm sieve, and the resultant powder micronised through a jet mill to particles of about 2 microns in diameter.

-12-

## EXAMPLE 2

### *Pharmacokinetic studies*

5        2.1. *Powder formulation and inhalation system*

Human PTH 1-84 or PTH 1-34 were prepared according to Examples 1.1 and 1.3, respectively. The powder formulations were compressed in dust containers and generated continuously as dry powder aerosols by a Wright 10 Dust Feed (WDF). The aerosols were generated by scraping off the formulations from the tablets in the dust containers. The mass flow through the WDF was 8.0 l/min.

15        The inhaled dose (ID) was determined by measuring the inspiratory tidal volume (ITV) and the PTH concentration during inhalation.

2.2. *Treatment*

20        Beagle dogs (n=5, at each formulation) were starved for 16 hours before inhalation and the experiments were performed in the mornings. The dogs were anaesthetized with Plegecil® and Pentotal®, intubated and exposed with either PTH 1-34 or PTH 1-84 for about 10 minutes.

25        Venous blood samples for determination of PTH concentration were taken from the jugular vein into heparinized vacutainer tubes (2 ml). The samples were collected before dosing and at 10, 15, 20, 30, 40, 60, 90, 120, 240 and 360 minutes after start (t=0) of inhalation. The whole blood samples were centrifuged immediately, alternatively kept in ice water for maximum 20 minutes before centrifugation, and the plasma (1 ml) was 30 sampled for PTH analysis. PTH in plasma was analyzed using radioimmunoassay (RIA) kits.

—13—

The results (Table 1 and Fig. 1) clearly show that inhalation of both PTH 1-34 and PTH 1-84 results in a pulsatile serum profile similar to that obtained with subcutaneous administration of PTH, confirming that pulmonary administration of full-length PTH, or a PTH fragment having 5 substantially the biological activities of full-length PTH, will be effective for stimulating bone formation and for the treatment of osteoporosis.

### EXAMPLE 3

10      *Bone effect*

The bone effect is measured in ovariectomized osteopenic rats as mineral density as weight/volume of the distal femur after 4 weeks of administration; starting 6 weeks post ovariectomy. The obtained results 15 show that inhalation of full-length PTH has a significant effect on femur bone formation.

-14-

TABLE 1

Plasma concentration of PTH in dogs after inhalation of PTH 1-34 or PTH 1-84

5

Time (min)	PTH 1-34		PTH 1-84	
	Conc. (pM)	S.E.	Conc. (pM)	S.E.
10	0	8.0	1.82	3.4
	10	30.4	4.99	8.3
	15	47.4	5.20	11.4
	20	49.6	6.81	11.6
	30	44.6	8.55	9.6
15	40	36.2	6.84	7.9
	60	26.0	4.90	5.8
	90	17.0	2.05	4.1
	120	12.6	2.06	3.0
	240	6.0	1.76	2.2
20	360	7.6	2.93	2.6
				0.85

S.E. = standard error of mean

-15-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: ASTRA AKTIEBOLAG  
(B) STREET: Västra Mälarehamnen 9  
(C) CITY: Södertälje  
(E) COUNTRY: Sweden  
(F) POSTAL CODE (ZIP): S-151 85  
(G) TELEPHONE: +46-8 553 260 00  
(H) TELEFAX: +46-8 553 288 20  
(I) TELEX: 19237 astra s

(ii) TITLE OF INVENTION: Therapeutic Preparations for Inhalation

(iii) NUMBER OF SEQUENCES: 1

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 84 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(x) PUBLICATION INFORMATION:

(H) DOCUMENT NUMBER: EP 0323751 B  
(I) FILING DATE: 07-OCT-1987  
(J) PUBLICATION DATE: 09-MAR-1994  
(K) RELEVANT RESIDUES IN SEQ ID NO: 1: FROM 1 TO 84

(x) PUBLICATION INFORMATION:

(H) DOCUMENT NUMBER: WO 94/07514  
(I) FILING DATE: 29-SEP-1993  
(J) PUBLICATION DATE: 14-APR-1994  
(K) RELEVANT RESIDUES IN SEQ ID NO: 1: FROM 1 TO 38

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn  
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His  
20 25 30

Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser  
35 40 45

Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu  
50 55 60

—16—

Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys  
65 70 75 80

Ala Lys Ser Gln

## CLAIMS

1. A therapeutic preparation comprising as active substance or substances (i) a parathyroid hormone, having substantially the biological activities of the full-length parathyroid hormone, and optionally (ii) a substance which enhances the absorption of PTH in the lower respiratory tract, said active substance or substances being in the form of a dry powder suitable for inhalation in which at least 50% of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates of such particles.  
5
2. A therapeutic preparation according to claim 1, characterised in that the dry powder contains, in addition to the active substances, a pharmaceutically acceptable carrier.  
10
3. A therapeutic preparation according to claim 2, characterised in that said carrier consists of particles having a diameter of up to 10 microns such that at least 50% of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates of such particles.  
15
4. A therapeutic preparation according to claim 3, in which at least 50% of the dry powder consists of (a) particles having a diameter of between 1 and 6 microns or (b) agglomerates of such particles.  
20
5. A therapeutic preparation according to claim 2, characterised in that said carrier consists of coarse particles, such that an ordered mixture may be formed between said active compounds and the carrier.  
25
6. A therapeutic preparation according to claim 1 or claim 5, in which at least 50% of the total mass of parathyroid hormone consists of particles having a diameter of between 1 and 6 microns.  
30


-18-

7. A therapeutic preparation according to any one of claims 1 to 6, characterised in that the parathyroid hormone has an amino acid sequence which is at least 90% homologous to the sequence shown as SEQ ID NO: 1 in the Sequence Listing.  
5
8. A therapeutic preparation according to any one of claims 1 to 6, characterised in that the parathyroid hormone is a human parathyroid hormone which comprises at least amino acids 1 to 34 of the sequence shown as SEQ ID NO: 1 in the Sequence Listing.  
10
9. A therapeutic preparation according to claim 7 or 8, characterised in that the parathyroid hormone is a human parathyroid hormone which comprises amino acids 1-84 of the sequence shown as SEQ ID NO: 1 in the Sequence Listing.  
15
10. A therapeutic preparation according to claim 2, characterised in that the carrier is selected from mono-, di-, and polysaccharides, sugar alcohols and other polyols.  
20
11. A therapeutic preparation according to claim 2, characterised in that the carrier is lactose.  
12. Use of a therapeutic preparation according to claim 1 in an inhalation device.  
25
13. Use according to claim 12, characterised in that the inhalation device provides protection of the powder for inhalation from moisture, and has minimal risk of overdosing.  
30
14. Use according to claim 13, characterised in that the inhalation device is a unit dose, breath actuated, dry powder inhaler for single usage.

—19—

15. Use according to claim 13, characterised in that the inhalation device is a multi dose, breath actuated, dry powder inhaler for multiple use.
16. A dry powder inhalation device containing the therapeutic preparation of claim 1.
17. A process for the manufacture of a therapeutic preparation according to claim 1, comprising forming a solution of parathyroid hormone, removing the solvent by evaporation or otherwise to obtain a solid, and optionally grinding the said solid.
18. A process according to claim 17 wherein the said solution is formed of parathyroid hormone together with at least one pharmaceutically acceptable carrier.
19. A process for the manufacture of a therapeutic preparation according to claim 2, comprising dry-mixing PTH together with a pharmaceutically acceptable carrier, and optionally grinding and/or mixing the said solid.
20. A process according to any one of claims 17 to 19, comprising the additional step of micronising the preparation.
21. A process according to claim 18 or 19, comprising the additional step of preparing an ordered mixture between the parathyroid hormone and the pharmaceutically acceptable carrier.
22. A method for the treatment of osteoporosis comprising administering, to a patient in need thereof, an effective amount of a preparation according to claim 1.

1 / 1



## INTERNATIONAL SEARCH REPORT

International application No. PCT/SE 95/01475
--

A. CLASSIFICATION OF SUBJECT MATTER		
<b>IPC6: A61K 9/72, A61K 38/29, A61K 47/12</b> According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE, DK, FI, NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
EMBASE, MEDLINE, WPI, WPIL, CLAIMS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9407514 A1 (INHALE THERAPEUTIC SYSTEMS), 14 April 1994 (14.04.94), page 4, line 1 - page 5, line 26; page 8, line 27 - page 10, line 5  --	1-21
A	WO 9500128 A1 (ASTRA AKTIEBOLAG), 5 January 1995 (05.01.95)  -----	1-21
<input type="checkbox"/> Further documents are listed in the continuation of Box C.		<input checked="" type="checkbox"/> See patent family annex.
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search  <b>22 March 1996</b>		Date of mailing of the international search report  <b>27 -03- 1996</b>
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86		Authorized officer  <b>Anneli Jönsson</b> Telephone No. + 46 8 782 25 00

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/SE 95/01475

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 22  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**  

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

05/02/96

International application No.

PCT/SE 95/01475

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9407514	14/04/94	NONE	
WO-A1- 9500128	05/01/95	NONE	